Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NasoShield Safety and Immunogenicity Study
NCT04415749Phase 1Completed
- Sponsor
- Altimmune, Inc.
- Start
- Jun 2020
- Primary completion
- Mar 2021
- Modality
- Prophylactic Vaccines, Nanoparticles, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nasoshield in anthrax (6 arms), sponsored by Altimmune, Inc. Primary endpoints: Reactogenicity at 7 days and Adverse Events. Started Jun 2020; status: completed.
02
Drugs
nasoshield
03
Conditions
anthrax
Beyond the preview
Go deeper on NCT04415749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04415749.